TOP TEN perturbations for 3500 (Homo sapiens)

Organism: Homo sapiens
Gene: 3500
Selected probe(set): 228518_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 3500 (228518_at) across 5392 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):6.249378
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):5.071213
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-4.834013
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):4.3758554
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

Burkitt lymphoma study 2 (immunodeficiency-associated) / Burkitt lymphoma study 1 (endemic)

Relative Expression (log2-ratio):3.9730883
Number of Samples:2 / 13
Experimental Burkitt lymphoma study 2 (immunodeficiency-associated)
Tumor tissue samples from the lymph node of children with immunodeficiency-associated Burkitt lymphoma (ID-BL).
Control Burkitt lymphoma study 1 (endemic)
Tumor tissue samples from the lymph node of children with endemic Burkitt lymphoma (eBL).

immune cell study 6 (PB; memory) / immune cell study 6 (PB; CD21hi)

Relative Expression (log2-ratio):3.7573757
Number of Samples:2 / 2
Experimental immune cell study 6 (PB; memory)
Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control immune cell study 6 (PB; CD21hi)
Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21hi) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21hi.

Roberts syndrome study 1 / normal lymphoblastoid cell line sample

Relative Expression (log2-ratio):-3.1738625
Number of Samples:2 / 18
Experimental Roberts syndrome study 1
Lymphoblastoid cell line samples from probands with Roberts syndrome (RBS).
Control normal lymphoblastoid cell line sample
Lymphoblastoid cell line samples from healthy subjects.

immune cell study 10 (IgG memory B-cell) / immune cell study 10 (naive B-cell)

Relative Expression (log2-ratio):2.7958746
Number of Samples:5 / 5
Experimental immune cell study 10 (IgG memory B-cell)
Class switched IgG memory B-cells (IgG+CD27+) isolated from peripheral blood of healthy adult donors (between 25 and 60 years of age). Mononuclear cells were isolated by Ficoll?Paque density centrifugation and CD19+ B-cells were enriched by magnetic cell separation using the MACS system or by negative selection using the EasySep Human B-Cell Enrichment Kit. B-cell suspensions were stained with anti-CD27 APC, anti-IgD PE?Cy7, anti-IgM FITC, and anti-IgG PE or anti-CD21 PE antibodies and sorted with a FACSDiva cell sorter as class switched IgG memory B-cells.
Control immune cell study 10 (naive B-cell)
Naive B-cells (IgM+IgD+CD27-) isolated from peripheral blood of healthy adult donors (between 25 and 60 years of age). Mononuclear cells were isolated by Ficoll?Paque density centrifugation and CD19+ B-cells were enriched by magnetic cell separation using the MACS system or by negative selection using the EasySep Human B-Cell Enrichment Kit. B-cell suspensions were stained with anti-CD27 APC, anti-IgD PE?Cy7, anti-IgM FITC, and anti-IgG PE or anti-CD21 PE antibodies and sorted with a FACSDiva cell sorter as naive B cells.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):2.7547474
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

immune cell study 6 (PB; memory) / immune cell study 6 (PB; CD21lo)

Relative Expression (log2-ratio):2.7536068
Number of Samples:2 / 2
Experimental immune cell study 6 (PB; memory)
Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control immune cell study 6 (PB; CD21lo)
Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo.